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ABSTRACT  
We analyzed the efficacy and applicability of surgery guided by 5-aminolevulinic acid 
(ALA) fluorescence in consecutive patients with glioblastoma multiforme (GBM). 
Thirty-six patients with GBM were operated on using ALA fluorescence. Resections 
were performed using the fluorescent light to assess the right plane of dissection. In 
each case, biopsies with different fluorescent quality were taken from the tumor center, 
from the edges, and from the surrounding tissue. These samples were analyzed 
separately with hematoxylin–eosin examination and immunostaining against Ki67. 
Tumor volume was quantified with pre- and postoperative volumetric magnetic 
resonance imaging. Strong fluorescence identified solid tumor with 100% positive 
predictive value. Invaded tissue beyond the solid tumor mass was identified by vague 
fluorescence with 97% positive predictive value and 66% negative predictive value, 
measured against hematoxylin–eosin examination. All the contrast-enhancing volume 
was resected in 83.3% of the patients, all patients had resection over 98% of the volume 
and mean volume resected was 99.8%. One month after surgery there was no mortality, 
and new or increased neurological morbidity was 8.2%. The fluorescence induced by 5-
aminolevulinic can help to achieve near total resection of enhancing tumor volume in 
most surgical cases of GBM. It is possible during surgery to obtain separate samples of 
the infiltrating cells from the tumor border. 
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INTRODUCTION 
 
The value of cytoreductive surgery in GBM is still extensively debated. Most of the 
recent literature agrees that resection of all the gadolinium-enhancing tumor verified by 
early magnetic resonance image (MRI) is a predictor of survival, but the evidence is 
weak, as it is mostly based on retrospective, observational studies [1–3]. The benefit 
shown could be a consequence of the treatment or the effect of smaller, superficial, non-
eloquent tumors in younger patients having better prognosis from the beginning and 
greater resections. However, in 2008, analysis of data from a randomized controlled 
trial (RCT) using the 5-aminolevulinic (ALA) fluorescence-guided resection (FGR) 
provided level 2b evidence supporting the influence of total resection on survival [4]. 
 
Objective measurement of residual tumor after surgery is still missing in many 
neurooncology trials, and the published rates of gross total resection (GTR) are low. A 
recent review cited only three papers publishing volumetric analysis of the extent of 
resection with more than 75 GBM cases [3]. In those studies, the frequency of verified 
GTR was 21, 33, and 49% (last figure for resections over 98%). 
 
New techniques are needed to improve resection rates. A RCT by the ALA study group 
in Germany proved the benefit of ALA-induced FGR in GBM [5]. The 65 versus 36% 
GTR rate achieved was enough to achieve significance. In this trial, an exclusion 
criteria was “tumor location did not enable complete resection of contrast-enhancing 
tumor as decided by individual study surgeon”. That criterion can leave some doubt 
about the applicability of the technique, and residual tumor was still found in 35% of 
cases judged to be resectable. We think this does not reflect the true potential of the 
technique. In that study, some centers performed better, with GTR over 80% (W. 
Stummer, personal communication, unpublished data). We studied the applicability and 
potential of ALA-guided surgery in a series of consecutive patients diagnosed of GBM 
in our center. 
 
 
 
MATERIALS AND METHODS 
 
From October 2007 to June 2009, we screened for surgery with ALA all patients 
consulting in our center whose MRI were suggestive of GBM. 
 
Resectability was decided over contrast-enhanced MRI (T1Gd MRI) images. A patient 
was considered a candidate for surgery if T1Gd MRI showed a definite, unilateral mass 
not invading thalamus or brain stem. In some cases with small satellite nodules or 
diffuse enhancing tissue affecting eloquent areas, surgery was advised if more than 90% 
of the T1Gd volume could be included in the target volume. Flair and T2 sequences 
were reviewed for evidence of big diffuse extension, in doubtful and in recurrent cases, 
C11-methionine positron emission tomography (met-PET) was done to precisely 
measure the tumor extension. 
 
We excluded from surgery patients with bilateral tumor, multiple distant lesions, 
subependimal spreading or tumors with small contrast-enhancing lesions and very 
extensive diffuse component. 
We did not exclude patients with T1Gd-enhancing mass that reached the ventricle or the 
corpus callosum if it did not have bilateral or subependimal spreading in T1Gd 
sequence. 
 
All cases were planned with the Brainlab navigation system. The T1Gd volume was 
manually segmented in BrainLab station and measured with the iplan cranial 2.6 
software. The neurosurgeon responsible for the case drew the abnormal enhancing area 
in each MRI slice; the final volume included all the enhancing area and the necrotic 
tissue within it. This was the preoperative tumor volume used in the volumetric 
calculations. In two cases, the target for surgery excluded small parts (0.25 and 0.2 ml) 
of the enhancing volume. 
 
We counted as newly diagnosed GBM cases the patients receiving their first operation 
or having a previous biopsy or partial resection in another center, but no previous 
radiotherapy nor chemotherapy, Patients with tumors recurrent after at least 
radiotherapy or chemotherapy treatment were grouped as recurrent GBM. 
 
The patient management was standard except for the oral administration of 20 mg/kg 5-
aminolevulinic acid 2–4 h before surgery, as published [6]. All surgeries were 
performed with a Zeiss Pentero microscope equipped with a fluorescent 400 nm UV 
light and filters. BrainLab navigation was used in every case, but when PET was 
available, the met-PET was fused to the MRI in the Brainlab station and both MRI and 
PET were used during surgery. Intraoperative MRI was not used. 
 
In all cases, we worked following the border of the tumor, keeping the dissection just 
outside it. We performed debulking of the tumor only if it was necessary to achieve a 
relaxed brain. When possible, we evacuated CSF from arachnoid cisterns before doing 
debulking. In cases that needed debulking, we went back to the border dissection as 
soon as the brain was relaxed enough. Ultrasonic aspiration was not used. We worked 
most of the time under the normal white light, but switched frequently to the UV light to 
assess the limit of the tumor with the fluorescent light and establish the right dissection 
plane. 
 
During surgery, we used the different fluorescent qualities described previously [7]: 
solid fluorescence (bright red), vague fluorescence (shades of pink) and non-fluorescent 
tissue (blue), to obtain separate samples from the center of the tumor, from the vague 
fluorescence regions at the edges of the tumor, and from the non-fluorescent tissue 
adjacent to it (Fig. 1b, c). These samples were sent for separate analysis including 
optical microscope examination and Ki67. In all cases, at least one sample was taken 
from the most peripheral part of tumor shown, the last fluorescent millimeters, and from 
the first millimeters of normal looking tissue. One experienced neuropathologist 
(M.I.G.), who was blinded to the fluorescent or non-fluorescent quality of the tissue, 
analyzed all the samples. This study includes only the patients diagnosed of GBM by 
WHO criteria. 
 
We obtained pre- and post-contrast MRI less than 72 h after surgery in every case, most 
cases before 36 h. Post-operative MRI was exported to the Brainlab station, and 
precontrast and postcontrast T1 images were compared. Although the diffuse nature of 
GBM is well known, the previous work on the benefit of surgical resection has been 
made using the T1Gd volume, which is the present target of surgery, so we used only 
this volume. Enhancing areas were considered tumor except for obvious vessel images. 
The residual tumor volume was segmented manually in each slice and measured by the 
iplan cranial 2.6 software. 
  
Two neuroradiologists (R.G.E. and P.D.E.) measured the residual tumor. Mean 
interobserver difference in the residual tumor volume measurements was 0.14 ml (0–1.9 
ml), the mean interobserver variability was 56% of the residual tumor volume. The 
mean variability amounts to 0.2% of the preoperative volume. After review of the 
discrepancies, both observers agreed in the cases which were considered GTR; the mean 
of both measurements was used for the rest. Resection was calculated as percent change 
of residual tumor over preoperative T1Gd volume in all cases. 
 
Neurological evaluation was used to measure clinical status before surgery, at 1 week 
and 1 month after surgery. 
 
After surgery, first-line patients received radiotherapy plus temozolomide treatment, 
except patient no. 9 who refused. Recurrent patients and most first-line at progression 
received irinotecan plus bevacizumab. No patient had reoperation. 
 
All patients gave informed consent for the study procedure. 
 
 
 
RESULTS  
 
Surgery 
 
Of the patient with suspected high grade glioma evaluated by the recruiting 
neurosurgeons during the study period, 7 patients had biopsy only (4 GBM, 2 
limphoma, 1 anaplastic astrocitoma), and 42 had resection surgery. Of 42 patients 
undergoing resection, 36 were GBM and are the basis for this report, while 6 had 
different grade three gliomas. In total, 90% of all the GBM underwent resection surgery. 
Of the 36 cases, 28 were newly diagnosed cases and 8 patients had recurrent tumors. 
Table 1 summarizes the clinical data of the patients. 
 
We could differentiate in all cases the three different fluorescent qualities, with neat 
distinction of the solid mass of the tumor in bright red, and the border in shades of pink. 
The pink areas were variable from one case to another and from some regions of the 
tumor to others, but in every case, some border area could be identified. In the tumors 
that reached the ventricle, there was always a wide surrounding pink area and the 
ventricular wall was at least partly fluorescent. The recurrent tumors had wider pink 
areas and less intense bright in the center. When radionecrosis was present, bright spots 
of viable tissue were mixed with necrotic, non-fluorescent tissue. 
 
 
Histology 
 
Table 2 summarizes the pathological diagnosis of the samples. A total of 72 samples 
with bright, red fluorescence were analyzed and corresponded always to solid tumor 
with the diagnostic criteria of GBM. A total of 73 samples from the edge of the pink 
areas were analyzed. In 2 small samples with very slight fluorescence from the same 
patient, the tissue was normal. In the remaining 71, the tissue was abnormal and 90% of 
the times, these areas had pathological features different from the core of the tumor. The 
biopsies were included in one spectrum going from highly cellular, with mitosis and 
atypical features, to only a slight increase in cellularity (Fig. 1d). The tumor cells at the 
edge looked less atypical than the tumor cells in the center of the lesion. Taken out of 
context, these would have been diagnosed as low grade astrocytoma. 
 
A total of 36 samples were taken from the non-fluorescent tissue adjacent to the last 
fluorescent pieces. It was difficult to assess the presence of tumor in these areas, and 
66% were diagnosed as normal tissue by routine hematoxylin–eosin. In the pathological 
33%, the tissue was classified as abnormal on the basis of isolated atypical cells or a 
slight increase in cell density (Fig. 1f). 
 
Using hematoxylin–eosin as the gold standard, red samples had 100% positive 
predictive value (PPV) for solid tumor, pink samples 97% PPV for tumor, and non-
fluorescent samples had 66% negative predictive value (NPV) for tumor. There was 
significant correlation between fluorescence and histology with P < 0.001 by Spearman 
test. 
 
 
Immunohistochemical study 
 
Proliferative index was assessed by Ki 67 (Fig. 1g–i). The index of marked cells was 
23.94 [confidence intervals (CI) 95% 15–33) in the central areas; 6.23 (CI 95% 4–9) in 
the vague fluorescence areas; and 1.67 (CI 95% 0.9–2.5)] in the blue areas. The 
differences between red and pink and pink and blue areas were significant at P < 0.001 
by t test (Fig. 2). Only 31% of the normal-looking areas were negative with Ki 67. 
 
 
Radiology 
 
The mean preoperative tumor volume was 51.18 ml (7.3–110). Total resection was 
achieved in 83.3% of the cases (30/36). The resection was greater than 98% of pre-
operative tumor volume in all the cases. Mean resection in the 36 patients was 99.8%. 
The mean postoperative tumor volume in the six cases with remnants was 0.56 ml 
(0.21–1.8). Figure 3 shows some illustrative cases. 
 
 
Safety 
 
There was no mortality at 1 month in our series. We had a new neurological deficit after 
surgery in 11.1% of our patients, and another 13.8% had worsening of a previous 
deficit. At 1 month, six out of these nine patients had recovered and only three patients 
(8.2%) were worse than before surgery, while 13 (36.1%) had recovered from 
preoperative deficits, and were better than before (Table 3). The new deficits at 1 month 
were a left hemiparesis, a left leg paresis and a dysphasia. 
 
 
 
Survival 
 
Mean KPS was 70 and mean age was 58. Cumulative survival duration and progression-
free survival from the time of surgery at our institution was computed using the 
Kaplan–Meier method. Survival was analyzed separately for first treatment and 
recurrent cases. Mean progression-free survival for newly diagnosed GBM was 6.5 
months (95% CI 3.8–9.2) and for recurrent cases 5.3 months (95% CI 4.4–6.2), Fig. 4 
shows the Kaplan–Meier curve. Median survival for newly diagnosed GBM was 15.7 
months (95% CI 5.3–26.1) and for recurrent GBM, 7.9 months (95% CI 7.2–18.4), Fig. 
5 shows the Kaplan– Meier curve.  
 
 
DISCUSSION 
 
Despite limitations in the quality of data, growing evidence suggests that more 
extensive surgical resection is associated with longer life expectancy for GBMs in 
retrospective papers [1, 2], literature review, [3] and a cohort study [4]. Volumetric 
analysis suggests that resection correlates with longer survival only if it exceeds 90% of 
tumor volume measured as T1Gd, and the benefit is maximal when resection is more 
than 98% [2]. Data from the EORTC-NCIC trial show that the benefit from 
radiotherapy (RT) plus temozolomide (TMZ) is greater in patients with GTR [8]. 
 
GTR should be the goal in every patient, if it can be done with a low risk of permanent 
neurological deficit. Early MRI should be performed in every case, to provide an 
adequate prognosis for the individual and to stratify patients properly in clinical trials 
for new therapies. A recent review [3] cited only three papers with volumetric 
measurement of residual tumor by post-operative MRI, and more than 75 cases with 
frequency of verified total resection of 23% [9], 33% [10], and 49% (this for resections 
over 98% of tumor volume) [2]. Other studies with resection measured by postoperative 
MRI, but smaller number of cases or non-volumetric analysis, have published similar 
rates of GTR, with best rates around 35% [11, 12], so a majority of the patients do not 
get GTR. This leaves the question as to how to improve the rate of GTR. 
 
Fluorescence-guided resection of GBM using ALA is a technique developed in 1998 [6, 
7]. Using ALA FGR offers real time viewing of the tumor in the operative field so we 
thought this system should allow us to resect almost all the tumor in most cases. Our 
results support this hypothesis as 83% of our patients had no residual tumor, mean 
volume resected was 99.8%, and all our patients got more than 98% resection, the limit 
for maximum benefit found in the largest series to date [2]. Our patients are 
representative of a good number of GBM cases, as the only criteria for inclusion in this 
study was resection surgery and the criteria for surgery used were wide. We tried to use 
indications for resection which were wide and reproducible, although a totally objective 
evaluation is not possible. Only 10% of the cases in the study period had not had 
resection surgery. We are a private center in a country with free public health care and 
many of our patients are second opinion cases rejected for surgery in other hospitals. 
The mean volume was 51 ml, mean KPS was 70 and mean age was 58, so this was not 
an especially favorable group of patients. 
 
We made a parallel pathological study to verify the correlation of fluorescence and 
histology. The 100% positive predictive value (PPV) for solid tumor, 97% PPV for 
invasive areas in the border, and 66% negative predictive value (NPV) of non-
fluorescent tissue, provides a rational, very solid foundation for the efficacy of the 
technique. We found no significant difference in biopsies of recurrent tumors; a recent 
paper also found a good correlation in recurrence [13]. The neurosurgeon can be sure 
that all the bright red tissue is solid tumor, without normal parenchyma so it can be 
resected, even near eloquent areas, and the vague fluorescence areas correspond with 
areas where tumor cells infiltrate brain tissue, the interface between tumor and brain. In 
eloquent areas. This vague fluorescence was not resected, and mostly was not visible in 
postoperative-MRI, as published previously [6], suggesting that vague fluorescent tissue 
is outside the gadolinium-enhancing border of the tumor. 
 
For the first time, the neurosurgeons have a tool which allows them to see the border of 
heavy infiltration, and these areas can be resected where not eloquent, which could 
allow for more extensive GTR that the actual standard targeting of the T1Gd area. It 
remains to be seen whether this extended GTR will give some additional benefit 
regarding survival. A recent report found that GTR verified by PET can impact survival 
more than total GTR verified by MRI [14]. A correlation may exist between ALA 
fluorescence and amino acid-PET [15]. 
 
In our non-fluorescent biopsies, the 66% NPV changed dramatically when we studied 
the samples with Ki-67 showing tumor cells beyond our “extended GTR” in 69% of the 
cases. This reminds us that any surgical border in GBM is going to leave residual cells. 
The invasive cells surrounded by normal tissue are different from the center so the 
response to treatment could be different [16]. To be successful, any adjuvant therapy 
should target these remaining cells. The ability to see the border also offers an 
opportunity for selective sampling of the invading cells in good quantity and in all 
cases. The study of these cells could offer new insights into the mechanism of this 
disease. 
 
This study was not designed to evaluate survival, yet the data of PFS and OS compare 
favorably with reference series in GBM [17]. 
 
Greater resections can entail increased risk for the patient. With ALA fluorescence, we 
actually “see” the tumor, including diffuse infiltrating areas where the tumor cells mix 
with normal brain. We do not think fluorescence here is a problem but an advantage; 
this is an old problem for neurosurgeons which is improved by a new tool, which helps 
them to know which areas are solid tumor and which are diffuse invasion. If the tumor 
approaches an eloquent area, the vague fluorescence should be left behind or the surgery 
may be performed cautiously with neurophysiological monitoring, which can be used at 
the same time that ALA surgery with good results [18]. Our immediate neurological 
morbidity was high at 25%, but the majority of the deficits were transitory; at 1 month, 
it was 8.2%. In the Glioma Outcome Project, neurological morbidity at 21 days was 
8.1% for first craniotomy and 18% for second [19]. Having more complete resection 
allows for less edema and less risk of bleeding postoperatively; we did not have any 
postoperative bleeding, postoperative symptomatic edema, or new postoperative 
seizures. 
 
Neurosurgeons have looked for years for techniques to see the tumor in the field, most 
of which have never achieved wide usage. To our knowledge, this is the only system 
tried in a randomized study. At this moment, FGR could be compared to intraoperative 
MRI (iMRI) and to other tumor-staining techniques. 
 
Using iMRI with low field iMRI, 22 out of 28 GBM patients (78%) had GTR in a 
recent report [20]. Mean volumetric resection of 94% [21] and 99% in GBM [22] have 
been achieved with high field magnets. A comparison between iMRI and FGR with 
evaluation of benefit and cost of each system would be interesting but is beyond the 
scope of this paper. 
 
Recent reports have given credit to two other fluorescent systems, sodium fluorescein 
and 5-aminofluorescein coupled to albumin. Fluorescein sodium has been used with 
encouraging results, although no randomized study has been completed [23–25]. In high 
doses, this has the advantage of not requiring special equipment. The authors have 
reported GTR rates of 83% [24], and 84% [25], but in selected cases and without 
volumetric data on the residues. The histological data are poor, since only four patients 
are included, and this technique is found to be less precise than ALA in visualizing the 
invasive border versus the “normal” area around the tumor. 
 
In the report on the use of 5-aminofluorescein-labeled albumin, the authors claim that 
their 81.8% GTR rate compares very favorably with the earlier 65% found in the RCT 
concerning ALA. Their data have only 10 GBM cases with 70% verified resection and 1 
case with control MRI not done. The present data compare favorably in resection, and in 
particular, the correlation with the histology results is much greater [26]. 
 
 
 
CONCLUSIONS 
 
With the limitations of the small size and single center nature of our data, the 
fluorescence produced by 5-aminolevulinic is a highly efficient and safe method of 
achieving maximal safe resection of GBM. Using this system, a majority of patients 
could have GTR, the only tumor remnants should be very small areas near eloquent 
tissue. 
 
With this technique, it is possible to obtain separate samples of the infiltrating cells of 
the border of the tumor during every surgery, which could be useful for new treatments 
needed in this disease. 
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Table 1. Summary of clinical data 
No. Diagnosis Age KPS 
Functional 
location 
grade
a
 
Resection 
(%) 
Residual 
tumor cc 
Follow-up PFS OS Status
b
 
Adjuvant 
therapy
c
 
1 GBM 59 60 I 100 0 29.6 5.3 9.4 DD R, T 
2 GBM 67 80 II 100 0 28.9 6.4 6.4 DO R, T 
3 GBM 57 30 III 100 0 27.2 5.8 6.7 DD R, IB 
e
 
4 GBM 34 90 I 100 0 25.9 4.7 7.7 DD R, T, IB 
5 GBM 61 80 II 100 0 25.6 16.8 20.8 DD R, T 
6 R. GBM 57 70 II 100 0 24.7 5.0 5.0 DD IB 
7 R. GBM 61 70 I 100 0 23.6 10.0 13.0 DD T
d
 
8 GBM 72 70 II 100 0 23.1 6.5 6.5 DD 
d 
9 GBM 69 90 II 100 0 22.6 >22.6 >22.6 PFS R, T 
10 GBM 36 40 III 100 0 22.5 8.4 15.7 DD R, T, IB 
11 GBM 71 70 III 100 0 21.9 >21.9 >21.9 PFS R, T 
12 GBM 72 70 II 99.8 0.2 21.2 14.2 >21.2 PD R, T, IB 
13 R. GBM 47 80 II 100 0 21.2 6.6 7.4 DD IB 
14 GBM 52 50 III 100 0 19.8 6.4 8.0 DD R, T 
15 R. GBM 66 90 III 100 0 19.8 3.7 3.7 DO IB 
16 R. GBM 43 80 II 98.6 0.9 18.2 5.3 15.6 DD T, IB 
17 GBM 49 100 II 100 0 17.3 >17.3 >17.3 PFS R, T 
18 R. GBM 62 40 II 100 0 16.3 1.1 1.1 DO 
f 
19 GBM 53 90 II 100 0 15.5 3.1 >15.5 PD R, T, IB 
20 GBM 63 70 II 98.5 0.3 15.0 14.7 >15 PD R, T 
21 GBM 30 60 II 100 0 14.7 >14.7 >14.7 PFS R, T 
22 GBM 69 70 I 100 0 14.4 4.4 4.4 DO R, T 
23 GBM 63 60 II 98.3 1.8 14.2 14.2 14.2 PFS R, T 
24 R. GBM 55 100 I 100 0 13.3 1.9 9.6 DD T, IB 
25 GBM 48 40 III 100 0 12.6 4.7 >12.6 PD R, T, IB 
26 GBM 70 90 II 100 0 11.2 5.9 6.6 DD R, T
e
 
27 GBM 69 70 II 100 0 11.0 >11 >11 PFS R, T 
28 R. GBM 59 60 III 100 0 10.3 5.6 7.9 DD T, IB 
29 GBM 59 80 III 100 0 10.0 4.7 >10 PD R, T, IB 
30 
 
GBM 
 
73 
 
70 
 
III 
 
99.3 
 
0.25  7.5 
 
3.1 
 
>7.5 
 
PD 
 
R, T, IB 
 31 GBM 71 40 III 100 0 6.8 1.1 1.1 DO 
f 
32 GBM 50 80 III 98.5 0.2 7.1 >7.1 >7.1 PFS R, T 
33 GBM 67 60 II 100 0 6.4 >6.4 >6.4 PFS R, T 
34 GBM 57 80 I 100 0 6.3 >6.3 >6.3 PFS R, T 
35 GBM 43 70 I 100 0 6.1 >6.1 >6.1 PFS R, T 
36 GBM 67 80 II 100 0 6.0 >6.0 >6.0 PFS R, T 
R. GBM Recurrent glioblastoma 
a
 Functional location grade according to Sawaya: I non-eloquent brain, II near eloquent, and III eloquent 
b
 Status at last follow-up: DD death from disease, DO death from other causes, PD progressive disease, PFS progression-free 
survival 
c
 Adjuvant therapy: R radiotherapy, T temozolomide, IB irinotecan + bevacizumab 
d
 Refused all or part of the treatment 
e 
Could not tolerate temozolomide 
f
 Death of associated problems before adjuvant therapy 
 Table 2. Histological results 
Histological diagnosis
a
 
Strong 
fluorescence* 
(bright red)     
n (%) 
Vague 
fluorescence* 
(pink)                    
n (%) 
No fluorescence* 
(blue)                        
n (%) 
Glioblastoma 72 (100%) 5 (6.9%) 0 
Astrocytic neoplasia (without 
criteria for grade 4) 
0 65 (90.3%) 12 (33% 
Normal 0 2 (2.8%) 24 (66%) 
a
 Diagnosis based on Hematoxylin–eosin staning 
* P < 0.001 for the difference between strong and vague fluorescence and between vague and 
no fluorescence (Mann–Whitney) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The three columns show the different qualities of tissue with fluorescent light. 
Upper row, surgical microscope photographs of: a bright fluorescence, b vague 
fluorescence, and c no fluorescence; in lower rows, the corresponding histology (d–f) 
and ki67 for the same section (g–i). 
 
 
 
 
Figure 2. Ki67 labeling index for the different fluorescent qualities. Bars show mean 
and CI 95%. 
 
 
Figure 3. Pre and postoperative MRI of some illustrative cases. From left to right, 
patient numbers 11, 10 and 3. 
 
 
 
 
Figure 4. Kaplan–Meier progression-free survival curve. 
 
 
 
 
Figure 5. Kaplan–Meier overall survival curve. 
